Agenus (AGEN) CMO Steven O'Day Receives 100,000-Share Award

What Happened
Steven J. O'Day, Chief Medical Officer of Agenus Inc., was granted a derivative award of 100,000 shares (reported as an "A" award) on 2026-08-05. The Form 4 records the acquisition price as $0.00, indicating an equity award/option rather than a cash purchase. The grant was reported on 2026-08-07 and does not involve an immediate sale or cash paid by the insider.

Key Details

• Transaction date: 2026-08-05; Form 4 filed: 2026-08-07 (timely filing).
• Transaction type/code: A (award/grant); 100,000 shares reported as a derivative award.
• Reported acquisition price: $0.00 (award/option, not a market purchase).
• Shares owned after the transaction: not specified in the provided filing details.
• Footnote: The award is granted under the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan and vests over three years — 1/3 on the first anniversary of the grant date, then the remaining 2/3 in two equal annual installments.

Context
This was an equity award (derivative option) subject to vesting, not an open-market buy or sale. Such grants are routine for executive compensation and do not by themselves indicate immediate buying or selling sentiment. If you want exercise price, accelerated vesting terms, or potential dilution impact, check the company’s proxy/compensation disclosures or the detailed grant agreement filed with the company.